176 related articles for article (PubMed ID: 22939663)
1. Impact of vaccination with seven-valent pneumococcal conjugate vaccine on virologic and immunologic outcomes among HIV-infected adult patients in the era of highly active antiretroviral therapy.
Lu CL; Chang SY; Sun HY; Liu WC; Tseng YT; Hsieh CY; Wu CH; Hung CC; Chang SC
J Formos Med Assoc; 2012 Aug; 111(8):445-51. PubMed ID: 22939663
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
[TBL] [Abstract][Full Text] [Related]
3. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.
Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Hsiao CF; Tseng YT; Su YC; Chang SF; Chang SY; Chang SC
Vaccine; 2012 May; 30(24):3526-33. PubMed ID: 22484349
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
[TBL] [Abstract][Full Text] [Related]
5. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
[TBL] [Abstract][Full Text] [Related]
6. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.
Lee KY; Tsai MS; Kuo KC; Tsai JC; Sun HY; Cheng AC; Chang SY; Lee CH; Hung CC
Hum Vaccin Immunother; 2014; 10(12):3700-10. PubMed ID: 25483681
[TBL] [Abstract][Full Text] [Related]
7. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.
Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Chang SY; Chang SC
Hum Vaccin Immunother; 2013 Feb; 9(2):398-404. PubMed ID: 23291936
[TBL] [Abstract][Full Text] [Related]
8. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.
Hung CC; Chang SY; Su CT; Chen YY; Chang SF; Yang CY; Liu WC; Wu CH; Chang SC
HIV Med; 2010 Jan; 11(1):54-63. PubMed ID: 19659943
[TBL] [Abstract][Full Text] [Related]
9. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
[TBL] [Abstract][Full Text] [Related]
10. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy.
Lu CL; Chang SY; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Hung CC
Vaccine; 2014 Feb; 32(9):1031-5. PubMed ID: 24440112
[TBL] [Abstract][Full Text] [Related]
11. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial.
Søgaard OS; Lohse N; Harboe ZB; Offersen R; Bukh AR; Davis HL; Schønheyder HC; Østergaard L
Clin Infect Dis; 2010 Jul; 51(1):42-50. PubMed ID: 20504165
[TBL] [Abstract][Full Text] [Related]
12. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy.
Søgaard OS; Schønheyder HC; Bukh AR; Harboe ZB; Rasmussen TA; Ostergaard L; Lohse N
AIDS; 2010 Jun; 24(9):1315-22. PubMed ID: 20559037
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
Glesby MJ; Watson W; Brinson C; Greenberg RN; Lalezari JP; Skiest D; Sundaraiyer V; Natuk R; Gurtman A; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
J Infect Dis; 2015 Jul; 212(1):18-27. PubMed ID: 25395187
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy.
Tangsinmankong N; Kamchaisatian W; Day NK; Sleasman JW; Emmanuel PJ
Ann Allergy Asthma Immunol; 2004 May; 92(5):558-64. PubMed ID: 15191025
[TBL] [Abstract][Full Text] [Related]
15. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine.
Rodriguez-Barradas MC; Alexandraki I; Nazir T; Foltzer M; Musher DM; Brown S; Thornby J
Clin Infect Dis; 2003 Aug; 37(3):438-47. PubMed ID: 12884170
[TBL] [Abstract][Full Text] [Related]
16. Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults.
Rossheim AE; Young AM; Siik J; Cunningham TD; Troy SB
Hum Vaccin Immunother; 2016 Aug; 12(8):2117-2123. PubMed ID: 27172241
[TBL] [Abstract][Full Text] [Related]
17. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study.
Falcó V; Jordano Q; Cruz MJ; Len O; Ribera E; Campins M; Crespo M; Ocaña I; Rodrigo MJ; Pahissa A
Vaccine; 2006 Mar; 24(14):2567-74. PubMed ID: 16423429
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998--2003.
Teshale EH; Hanson D; Flannery B; Phares C; Wolfe M; Schuchat A; Sullivan P
Vaccine; 2008 Oct; 26(46):5830-4. PubMed ID: 18786586
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults in the era of highly active antiretroviral therapy: analysis stratified by CD4 T-cell count.
Song JY; Cheong HJ; Noh JY; Choi MJ; Yoon JG; Kim WJ
Hum Vaccin Immunother; 2020; 16(1):169-175. PubMed ID: 31441710
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.
Lombardi F; Belmonti S; Fabbiani M; Morandi M; Rossetti B; Tordini G; Cauda R; De Luca A; Di Giambenedetto S; Montagnani F
PLoS One; 2016; 11(6):e0156523. PubMed ID: 27258647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
